Christy J. Ralph
St James's Hospital
Leeds, ENG, United Kingdom
Leeds, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 20, 2026
4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma.
Journal: BJC reports
Published: November 19, 2025
Apoptotic modulators enhance oncolytic virus-induced cytokine killing in acute myeloid leukaemia (AML).
Journal: British journal of cancer
Published: August 01, 2025
Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment.
Journal: Frontiers in immunology
Published: March 27, 2025
Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.
Journal: International journal of cancer
Published: January 28, 2025
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment.
Journal: Frontiers in immunology
Published: September 23, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
Journal: Health technology assessment (Winchester, England)
Published: September 09, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 16, 2024
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 22, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Journal: The Lancet. Oncology
Published: November 02, 2022
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.
Journal: Molecular therapy oncolytics
Published: October 19, 2022
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: October 14, 2022
Last Updated: 09/26/2026